NCT01894256 - Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

February 29, 2016

Conditions

Solid Tumours

Interventions

DRUG

Olaparib tablet dosing

Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd

Trial Locations (13)

Research Site, Brussels (Jette)

Research Site, Edegem

Research Site, Leuven

Research Site, Liège

Research Site, Wilrijk

Research Site, Herlev

Research Site, København Ø

Research Site, Bordeaux

Research Site, Dijon

Research Site, Amsterdam

Research Site, Maastricht

Research Site, Newcastle upon Tyne

Research Site, Surrey